Akèy › Limfòm selil B
Etid klinik pou Limfòm selil B ap rekrite nan Etazini
67 etid pou Limfòm selil B ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- New York City, NY19 etid
- Houston, TX16 etid
- Chicago, IL12 etid
- Nashville, TN11 etid
- Philadelphia, PA11 etid
- Rochester, MN10 etid
- Baldwin Park, CA9 etid
- Milwaukee, WI9 etid
- Boston, MA8 etid
- Cleveland, OH8 etid
- Washington, DC7 etid
- Denver, CO7 etid
- Salt Lake City, UT7 etid
- Dallas, TX7 etid
- Seattle, WA7 etid
- Columbus, OH7 etid
- Charlotte, NC7 etid
- Pittsburgh, PA7 etid
- Edison, NJ6 etid
- New Haven, CT6 etid
- Aurora, CO6 etid
- San Antonio, TX6 etid
- Los Angeles, CA6 etid
- Atlanta, GA5 etid
- Ann Arbor, MI5 etid
- Omaha, NE5 etid
- St. Louis, MO5 etid
- Kansas City, MO5 etid
- Mountain View, CA5 etid
- Jacksonville, FL4 etid
- Cedar Rapids, IA4 etid
- Tampa, FL4 etid
- Portland, OR4 etid
- Winston-Salem, NC4 etid
- Louisville, KY4 etid
- Cincinnati, OH4 etid
- Richmond, VA4 etid
- Indianapolis, IN4 etid
- Miami, FL4 etid
- Austin, TX3 etid
Pa eta
- Arizona5 etid
- Colorado11 etid
- Connecticut6 etid
- Distrik Columbia3 etid
- Florid15 etid
- Georgia7 etid
- Illinois12 etid
- Indiana5 etid
- Iowa6 etid
- Kalifòni20 etid
- Kansas9 etid
- Kentucky4 etid
- Maryland7 etid
- Massachusetts8 etid
- Michigan7 etid
- Minnesota12 etid
- Missouri5 etid
- Nebraska5 etid
- New Jersey9 etid
- New York21 etid
- North Carolina11 etid
- Ohio16 etid
- Oregon5 etid
- Pennsylvania16 etid
- Tennessee13 etid
- Texas26 etid
- Utah7 etid
- Virginia8 etid
- Washington10 etid
- Wisconsin10 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
Ap rekriteFaz 1/2
Laj 3 a 39 · Tout sèks · Mizajou Sep 30, 2026 · NCT05442515A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT06742996A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07439653Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT06350318Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
Ap rekriteFaz 2
Laj 60 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06052826A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06213311A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07101328A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT05615636A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
Ap rekriteFaz 1
Laj 0 a 18 · Tout sèks · Mizajou Sep 16, 2026 · NCT06173518UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
Ap rekriteFaz 1/2
31 Days – 30 Years · Tout sèks · Mizajou Sep 14, 2026 · NCT04544592Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT06526793A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT06634589Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT05272384Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT07225439A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT06564038A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT06393738Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma
Ap rekriteEtid obsèvasyon
Laj 4 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT07652580Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 31, 2026 · NCT07516093A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT07123454Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT07520006A Study of ARC-02 in B-cell NHL
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 26, 2026 · NCT07691606Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
Ap rekriteFaz 1
Laj 18 a 120 · Tout sèks · Mizajou Aug 25, 2026 · NCT05389423Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT05826535A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 24, 2026 · NCT07220616Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT04792502Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.